Meeting
2022 ASCO Annual Meeting
DSP-0390, an oral emopamil binding protein (EBP) inhibitor, in patients with recurrent high-grade glioma: A first-in-human, phase 1 study.
Authors
David A. Reardon
Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, MA
David A. Reardon , Yoshitaka Narita , Yoshiki Arakawa , Samuel A. Goldlust , George Ansstas , Jian Mei , Edward Dow , Masataka Seki , Yudai Furuta , Gregory Song , Howard Colman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT05023551
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2077)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2077
Abstract #
TPS2077
Poster Bd #
413a
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase I study to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activities of daily oral BAL101553, a novel tumor checkpoint controller (TCC) in adult patients with progressive or recurrent glioblastoma (GBM) or high-grade glioma.
First Author: Alvaro Henrique Ingles Garces
Poster
2022 ASCO Annual Meeting
Repeated opening of the blood-brain barrier with the skull-implantable SonoCloud-9 (SC9) device: Phase 1 trial of nab-paclitaxel and SC9 in recurrent glioblastoma.
First Author: Adam M. Sonabend
Poster
2020 ASCO Virtual Scientific Program
Escalation portion of phase II study to evaluate the safety, pharmacokinetics, and clinical activity of the PI3K/mTOR inhibitor paxalisib (GDC-0084) in glioblastoma (GBM) with unmethylated O6-methylguanine-methyltransferase (MGMT) promotor status.
First Author: Patrick Y. Wen
Poster
2016 ASCO Annual Meeting
A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma.
First Author: Patrick Y. Wen